Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Aquila Bioscience is a biotechnology company based in Galway, Ireland, that specializes in glycobiology-based pathogen capture and decontamination technologies. A spin-out from the National University of Ireland Galway, the company has developed a proprietary platform that uses nature-inspired carbohydrate-protein interactions to physically trap and neutralize harmful microorganisms, including bacteria, viruses, and fungi. Their lead commercial product, the ABD (Aquila Bioscience Decontamination) wipe, provides a non-toxic, alcohol-free alternative to traditional chemical disinfectants, making it safe for use on human skin and sensitive equipment. The technology is utilized by healthcare providers, defense forces, and commercial entities to enhance infection control and biosecurity. Aquila Bioscience continues to expand its platform for applications in diagnostics and environmental monitoring.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Aquila Bioscience.